普萘洛尔对BALB/C小鼠腹膜巨噬细胞分泌细胞因子及吞噬功能的影响

目的:探讨普萘洛尔对脂多糖诱导BALB/C小鼠腹膜巨噬细胞分泌肿瘤坏死因子(TNF)-α和白细胞介素(IL)-10以及吞噬功能的影响。方法:将腹膜巨噬细胞分为8组:空白组,脂多糖组,普萘洛尔(0.1μmol/L)组,普萘洛尔(1.0μmol/L)组,普萘洛尔(10.0μmol/L)组;普萘洛尔(0.1μmol/L)加脂多糖组,普萘洛尔(1.0μmol/L)加脂多糖组,普萘洛尔(10.0μmol/L)加脂多糖组。在培养6h和24h后用酶联免疫法测定各培养瓶上清液中TNF-α和IL-10的浓度,用中性红吞噬试验检测巨噬细胞吞噬功能。结果:空白组与单用普萘洛尔时,巨噬细胞均无细胞因子分泌(无数据显示),吞噬功能无明显影响。单用脂多糖组巨噬细胞释放TNF-α和IL-10显著增加,吞噬能力明显增强。而普萘洛尔加脂多糖组巨噬细胞继续分泌TNF-α,IL-10分泌减少,吞噬功能显著降低,该作用随普萘洛尔浓度增加而增强。结论:普萘洛尔可调节腹膜巨噬细胞炎症递质的分泌,并能影响腹膜巨噬细胞的吞噬能力。     

L'azione del propranololo sulla glicemia e sull'insulina immunoreattiva in una paziente affetta da insulinoma

Riassunto Con la somministrazione orale di propranololo ad una paziente affetta da insulinoma si è notato un miglioramento delle condizioni cliniche e una minor frequenza delle crisi ipoglicemiche. I valori di glicemia e di IRI si sono portati nella norma. Vengono riportati e brevemente discussi i risultati delle prove del digiuno, del glucagone e della leucina praticate prima e durante la somministrazione del propranololo.

---

Summary Oral administration of propranolol to a patient with insulinoma resulted in normalization of blood glucose and immunoreactive insulin and improvement in the patient's condition. Blood glucose and IRI levels returned normal. The results of fasting, glucagon and leucine tests performed before and during administration of propranolol are reported and briefly discussed.

---

Zusammenfassung Nach der oralen Verabreichung von Propranolol in einer Patientin mit Insulinom wurde eine Besserung der klinischen Daten sowie eine verminderte Haeufigkeit der hypoglykaemischen Krisen festgestellt. Die Werte des Blutzuckers sowie der IRI kehrten zur Norm zurueck. Es werden die Resultate der Proben des Fastens, des Glukagons sowie des Leuzins vor und waehrend der Verabreichung von Propranolol mitgeteilt und kurz diskutiert.

---

Resumen Suministrando por vía oral propranololo a una paciente enferma de insulinoma, se ha notado mejoría de las condiciones clínicas y menor frecuencia de las crisis hipoglucémicas. Los valores de glucemia y de IRI volvieron a su normalidad. Se reportan, y se discuten brevemente, los resultados de las pruebas del ayuno, del glucagón y de la leucina, efectuadas antes y durante la suministración de propranololo.

---

Resume Avec l'administration par voie orale de propranolole à une femme affecte de insulinome, les AA. ont observé une admélioration des conditions cliniques et une mineure fréquence des crises hipoglycémiques. Le taux de glycémie et de l'IRI sont redevenu normaux. On discute brièvement les résultats des épreuves du jeûne, du glucagone et de la léucine administrées avant et pendant le propranolole.

     

普萘洛尔对血管瘤内皮细胞的抑制作用

目的:探讨不同浓度普萘洛尔在不同时间段内对血管瘤内皮细胞的抑制作用。方法:收集手术切除的新鲜婴幼儿血管瘤标本,采用组织块法培养内皮细胞,免疫荧光法对培养的细胞进行鉴定;通过绘制生长曲线和流式细胞仪检测普萘洛尔(propranolol)对血管瘤内皮细胞增殖影响。结果:伴随普诺洛尔浓度增大(0μg/ml,20μg/ml,40μg/ml,60μg/ml,80μg/ml,100μg/ml,120μg/ml)及作用时间的增加(24h,48h,72h)对血管瘤内皮细胞的抑制作用明显增强;流式细胞仪测定不同浓度普萘洛尔作用不同时段后血管瘤内皮细胞凋亡明显。结论:普萘洛尔能抑制血管瘤内皮细胞的增殖并促进其凋亡,抑制血管瘤的生长。     

口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南

婴幼儿血管瘤(infantile hemangiomas, IH)是最常见的婴幼儿血管良性肿瘤。关于适应证、诊疗前检查、PHACES综合征的治疗、停药时间等,目前仍存在诸多分歧。本研究使用改进的德尔菲法(Delphi technique),包括国际性治疗方法调查,对已发表文献的系统评价、面对面多学科专家会谈以及匿名投票,就8大类条目共47项指南内容达成共识。本临床指南有助于标准化和简化口服普萘洛尔治疗婴幼儿血管瘤的过程,并且协助临床决策。     

普萘洛尔试验在鉴别中青年女性肿瘤患者心电图ST-T 改变性质中的应用

目的探讨普萘洛尔试验在鉴别未经治疗的中青年女性肿瘤患者心电图ST-T改变性质中的临床应用价值。方法选择154例年龄18～49岁,心电图具有非特异性ST-T改变,心率>80bpm的女性为研究对象,其中78例肿瘤患者标记为A组,76例健康女性标记为B组。在给予口服普萘洛尔20mg后,分别在30min、60min、120min记录心电图,比较服药后两组心电图ST-T的变化。结果 A组普萘洛尔试验阳性67例,阳性率为85.9%;B组普萘洛尔试验阳性70例,阳性率达92.1%,两组之间的差异无统计学意义(P>0.05)。结论普萘洛尔试验可以用于鉴别未经治疗的中青年女性肿瘤患者心电图ST-T改变的性质,与其应用于健康女性具有相似的临床价值。     

Beta adrenergic blockade reduces utilitarian judgement

Noradrenergic pathways are involved in mediating the central and peripheral effects of physiological arousal. The aim of the present study was to investigate the role of noradrenergic transmission in moral decision-making. We studied the effects in healthy volunteers of propranolol (a noradrenergic beta-adrenoceptor antagonist) on moral judgement in a set of moral dilemmas pitting utilitarian outcomes (e.g., saving five lives) against highly aversive harmful actions (e.g., killing an innocent person) in a double-blind, placebo-controlled, parallel group design. Propranolol (40 mg orally) significantly reduced heart rate, but had no effect on self-reported mood. Importantly, propranolol made participants more likely to judge harmful actions as morally unacceptable, but only in dilemmas where harms were ‘up close and personal’. In addition, longer response times for such personal dilemmas were only found for the placebo group. Finally, judgments in personal dilemmas by the propranolol group were more decisive. These findings indicate that noradrenergic pathways play a role in responses to moral dilemmas, in line with recent work implicating emotion in moral decision-making. However, contrary to current theorising, these findings also suggest that aversion to harming is not driven by emotional arousal. Our findings are also of significant practical interest given that propranolol is a widely used drug in different settings, and is currently being considered as a potential treatment for post-traumatic stress disorder in military and rescue service personnel.